# GentleGen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gentlegen

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.gentlegen.com
- Total disclosed funding: $14M
- Latest round: Series A (Dec 15, 2025)
- Investors on record: 6

## About

Founded in 2022 and based in Suzhou, China, Suzhou GentleGen Technology Co., Ltd., trading as GentleGen, operates as a biotechnology company, specializing in intelligent oligonucleotide synthesis CRDMO services. The company has accumulated dozens of patent applications. In March 2023, GentleGen acquired ISO 9001:2015 Quality Management System Certification and ISO 13485:2016 Quality Management System Certification for Medical Machinery. In December 2025, GentleGen raised approximately CNY 100 million in Series A funding co-led by new investors Tenykin Capital, Jiangsu Jinqiao Private Equity Fund Management and Jinhai Venture Capital, with participation from other new investor Hubei Science Technology Investment Group.

The company creates automated and intelligent biotechnology applications, combining advanced automation technology to create an intelligent one-stop gene service technology platform for gene synthesis, oligonucleotide synthesis, Sanger sequencing, high-throughput sequencing, gene editing and protein expression, accelerating the progress of life sciences R&D, and upgrading the synthetic biology industry. Meanwhile, GentleGen has established a comprehensive biopharmaceutical safety evaluation system for nucleic acid drugs, cellular and gene therapeutic drugs, gene editing drugs and protein drugs, from early R&D to clinical stage, to ensure the safety of biopharmaceuticals.

The company generates revenue by doing R&D, and providing automated gene technology applications and other related products and services.

The Series A funding raised in December 2025 will be primarily used for key business areas such as upgrading and improving fully automated production lines, developing and iterating core technologies, expanding the team, and expanding into global markets, further promoting the global deployment of automated genetic technology applications.

## Funding rounds

- Series A, Dec 15, 2025, $14M — Hubei Science Technology Investment Group, Tenykin Capital, Jiangsu Jinqiao Private Equity Fund Management, Jinhai Venture Capital
- Angel, May 11, 2023 — Orient Jiafu Asset Management, Suzhou Wuzhong Biomedical Industrial Park Investment

## Investors

- Orient Jiafu Asset Management (https://capitalatlas.ai/funds/orient-jiafu-asset-management) — Angel
- Suzhou Wuzhong Biomedical Industrial Park Investment — Angel
- Hubei Science Technology Investment Group — Series A
- Tenykin Capital (https://capitalatlas.ai/funds/tenykin-capital) — Series A
- Jiangsu Jinqiao Private Equity Fund Management (https://capitalatlas.ai/funds/jiangsu-jinqiao-private-equity-fund-management) — Series A
- Jinhai Venture Capital (https://capitalatlas.ai/funds/jinhai-venture-capital) — Series A